{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T17:17:33Z","timestamp":1763572653200,"version":"3.41.2"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>To cope with the decline in COVID-19 vaccine-induced immunity caused by emerging SARS-CoV-2 variants, a heterologous immunization regimen using chimpanzee adenovirus vectored vaccine expressing SARS-CoV-2 spike (ChAd-S) and an inactivated vaccine (IV) was tested in mice and non-human primates (NHPs). Heterologous regimen successfully enhanced or at least maintained antibody and T cell responses and effectively protected against SARS-CoV-2 variants in mice and NHPs. An additional heterologous booster in mice further improved and prolonged the spike-specific antibody response and conferred effective neutralizing activity against the Omicron variant. Interestingly, priming with ChAd-S and boosting with IV reduced the lung injury risk caused by T cell over activation in NHPs compared to homologous ChAd-S regimen, meanwhile maintained the flexibility of antibody regulation system to react to virus invasion by upregulating or preserving antibody levels. This study demonstrated the satisfactory compatibility of ChAd-S and IV in prime-boost vaccination in animal models.<\/jats:p>","DOI":"10.3389\/fimmu.2022.949248","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T05:45:01Z","timestamp":1660715101000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques"],"prefix":"10.3389","volume":"13","author":[{"given":"Qian","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qunying","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bopei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoqiang","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xujia","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinghuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lifang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yadi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jincun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianlian","family":"Bian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changgui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenglun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"B1","unstructured":"COVID-19 vaccine tracker and landscape"},{"key":"B2","unstructured":"Criteria for COVID-19 vaccine prioritization"},{"key":"B3","unstructured":"WHO coronavirus (COVID-19) dashboard"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2032195","article-title":"Durability of responses after SARS-CoV-2 mRNA-1273 vaccination","volume":"384","author":"Widge","year":"2021","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.1953403","article-title":"Antibody titres decline 3-month post-vaccination with BNT162b2","volume":"10","author":"Favresse","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.10.038","article-title":"COVID-19 vaccine - long term immune decline and breakthrough infections","volume":"39","author":"Khoury","year":"2021","journal-title":"Vaccine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj4176","article-title":"Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants","volume":"373","author":"Pegu","year":"2021","journal-title":"Sci (New York NY)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.chom.2021.03.009","article-title":"Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant","volume":"29","author":"Edara","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04387-1","article-title":"Omicron extensively but incompletely escapes pfizer BNT162b2 neutralization","volume":"602","author":"Cele","year":"2022","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.1c01451","article-title":"Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance","volume":"62","author":"Chen","year":"2021","journal-title":"ArXiv"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1640117","article-title":"Novel prime-boost vaccine strategies against HIV-1","volume":"18","author":"Excler","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.04.073","article-title":"Heterologous HA DNA vaccine prime\u2013inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses","volume":"26","author":"Wang","year":"2008","journal-title":"Vaccine"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02155-18","article-title":"Prime-boost immunizations with DNA, modified vaccinia virus Ankara, and protein-based vaccines elicit robust HIV-1 tier 2 neutralizing antibodies against the CAP256 superinfecting virus","volume":"93","author":"van Diepen","year":"2019","journal-title":"J Virol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans","volume":"595","author":"Sahin","year":"2021","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI149335","article-title":"SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63","volume":"131","author":"Woldemeskel","year":"2021","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1016\/j.vaccine.2010.02.006","article-title":"Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity","volume":"28","author":"Vaine","year":"2010","journal-title":"Vaccine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4161\/hv.21648","article-title":"DNA Prime-protein boost using subtype consensus env was effective in eliciting neutralizing antibody responses against subtype BC HIV-1 viruses circulating in China","volume":"8","author":"Zhang","year":"2012","journal-title":"Hum Vaccines Immunother"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.626464","article-title":"Modified adenovirus prime-protein boost clade c HIV vaccine strategy results in reduced viral DNA in blood and tissues following tier 2 SHIV challenge","volume":"11","author":"Malherbe","year":"2020","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.1902245","article-title":"Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates","volume":"10","author":"He","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.1957401","article-title":"Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine","volume":"10","author":"Zhang","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01677-z","article-title":"Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial","volume":"28","author":"Li","year":"2022","journal-title":"Nat Med"},{"year":"","key":"B24","article-title":"Status of COVID-19 vaccines within WHO EUL\/PQ evaluation process updated"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01464-w","article-title":"Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination","volume":"27","author":"Schmidt","year":"2021","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2021.1971522","article-title":"To mix or not to mix? a rapid systematic review of heterologous prime-boost covid-19 vaccination","volume":"20","author":"Chiu","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01449-9","article-title":"Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination","volume":"27","author":"Barros-Martins","year":"2021","journal-title":"Nat Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1743767","article-title":"Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2","volume":"9","author":"Nie","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"B29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41392-021-00611-6","article-title":"Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study","volume":"6","author":"Xu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41392-020-00269-6","article-title":"Comparison of nonhuman primates identified the suitable model for COVID-19","volume":"5","author":"Lu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.123158","article-title":"Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection","volume":"4","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41392-022-00926-y","article-title":"Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01194-5","article-title":"T Cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial","volume":"27","author":"Ewer","year":"2021","journal-title":"Nat Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-017-9487-9_6","article-title":"Tfh cell differentiation and their function in promoting b-cell responses","volume":"841","author":"Qi","year":"2014","journal-title":"Adv Exp Med Biol"},{"key":"B37","doi-asserted-by":"publisher","first-page":":001698","DOI":"10.1099\/jgv.0.001698","article-title":"Selection and T-cell antigenicity of synthetic long peptides derived from SARS-CoV-2","volume":"103","author":"Piadel","year":"2022","journal-title":"J Gen Virol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.07.033","article-title":"Highly conserved influenza T cell epitopes induce broadly protective immunity","volume":"37","author":"Eickhoff","year":"2019","journal-title":"Vaccine"},{"key":"B39","unstructured":"WHO\/BS.2020.2403 establishment of the WHO international standard and reference panel for anti-SARS-CoV-2 antibody"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01142","article-title":"T Cells in fibrosis and fibrotic diseases","volume":"11","author":"Zhang","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.163576","article-title":"Inflammation, immunity, and hypertension","volume":"49","author":"Agita","year":"2017","journal-title":"Acta Med Indonesiana"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2021.1903879","article-title":"Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies","volume":"20","author":"Bian","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2021.1976153","article-title":"Impact of the delta variant on vaccine efficacy and response strategies","volume":"20","author":"Bian","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"B44","doi-asserted-by":"publisher","first-page":"108035","DOI":"10.1016\/j.jmgm.2021.108035","article-title":"E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies","volume":"109","author":"Wang","year":"2021","journal-title":"J Mol Graphics Model"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00094-0","article-title":"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study","volume":"399","author":"Costa Clemens","year":"2022","journal-title":"Lancet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.949248\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T05:45:07Z","timestamp":1660715107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.949248\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2022.949248"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.949248","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2022,8,17]]},"article-number":"949248"}}